{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:11:17Z","timestamp":1789463477168,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00228-026-04169-6","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T01:42:20Z","timestamp":1787190140000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["\u201cPrescribers Beware\u201d: a narrative review of dangerous drug-drug-interactions involving psychotropic medications"],"prefix":"10.1007","volume":"82","author":[{"given":"Caiwei","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo","family":"Lee-Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"issue":"12","key":"4169_CR1","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S2215-0366(24)00314-6","volume":"11","author":"M H\u00f8jlund","year":"2024","unstructured":"H\u00f8jlund M et al (2024) Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis. Lancet Psychiatry 11(12):975\u2013989","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"4169_CR2","first-page":"26","volume":"67","author":"R Mojtabai","year":"2009","unstructured":"Mojtabai R, Olfson M (2009) National trends in psychotropic medication polypharmacy in office-based psychiatry. JAMA Psychiatry 67(1):26\u201336","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"4169_CR3","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/pds.5310","volume":"30","author":"JA-O Wolff","year":"2021","unstructured":"Wolff JA-O et al (2021) Polypharmacy and the risk of drug-drug interactions and potentially inappropriate medications in hospital psychiatry. Pharmacoepidemiol Drug Saf 30(9):1258\u20131268","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"4169_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12888-019-2056-0","volume":"19","author":"JA-O Carmona-Huerta","year":"2019","unstructured":"Carmona-Huerta JA-O et al (2019) Polypharmacy in a hospitalized psychiatric population: risk estimation and damage quantification. BMC Psychiatry 19(1):78","journal-title":"BMC Psychiatry"},{"issue":"9","key":"4169_CR5","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J et al (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45(9):789\u2013796","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"4169_CR6","doi-asserted-by":"publisher","first-page":"742","DOI":"10.3390\/ph18050742","volume":"18","author":"PA-O Waszak","year":"2025","unstructured":"Waszak PA-O et al (2025) Anti-Suicidal Effects of Lithium, Ketamine, and Clozapine-A 10-Year Systematic Review. Pharmaceuticals (Basel) 18(5):742","journal-title":"Pharmaceuticals (Basel)"},{"key":"4169_CR7","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.schres.2023.07.014","volume":"268","author":"WY Chen","year":"2024","unstructured":"Chen WY et al (2024) Clozapine and its protective effect on all-cause, natural, and suicide mortality in patients with schizophrenia: A nationwide cohort study in Taiwan. Schizophr Res 268:150\u2013160","journal-title":"Schizophr Res"},{"issue":"2","key":"4169_CR8","first-page":"113","volume":"55","author":"ME Wigard","year":"2013","unstructured":"Wigard ME, van Gool AF, Schulte PFJ, Schulte PF (2013) Addition of fluvoxamine to clozapine: theory and practice. Tijdschrift voor Psychiatrie 55(2):113\u2013121","journal-title":"Tijdschrift voor Psychiatrie"},{"issue":"5","key":"4169_CR9","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00213-015-4161-1","volume":"233","author":"C Polcwiartek","year":"2016","unstructured":"Polcwiartek C, Nielsen J (2016) The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review. Psychopharmacology 233(5):741\u2013750","journal-title":"Psychopharmacology"},{"key":"4169_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.schres.2019.05.033","volume":"210","author":"M Augustin","year":"2019","unstructured":"Augustin M et al (2019) Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations. Schizophr Res 210:143\u2013148","journal-title":"Schizophr Res"},{"key":"4169_CR11","first-page":"111","volume":"17","author":"ZX Yu","year":"2024","unstructured":"Yu ZX et al (2024) Clozapine-Induced Severe Toxicity: Exploring the Pharmacokinetic Profile of Clozapine and Its Significance in Hemodynamic Instability - A Case Report. Int Med Case Rep J 17:111\u2013120","journal-title":"Int Med Case Rep J"},{"issue":"Electronic","key":"4169_CR12","first-page":"1573","volume":"268","author":"H Verdoux","year":"2024","unstructured":"Verdoux H, Quiles C, de Leon J (2024) Optimizing antidepressant and clozapine co-prescription in clinical practice: A systematic review and expert recommendations. Schizophr Res 268(Electronic):1573\u20132509","journal-title":"Schizophr Res"},{"issue":"3","key":"4169_CR13","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1527-3458.2001.tb00200.x","volume":"7","author":"H Silver","year":"2001","unstructured":"Silver H (2001) Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev 7(3):283\u2013304","journal-title":"CNS Drug Rev"},{"key":"4169_CR14","unstructured":"FDA Drug Label: FLuvoxamine Maleate. (2025) August 4, 2025 [cited 2026; Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=7ecd83ec-88f5-4f85-9cc2-9068375d8820"},{"key":"4169_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.schres.2018.05.034","volume":"202","author":"G Shymko","year":"2018","unstructured":"Shymko G et al (2018) Navigating the co-prescription of clozapine and fluvoxamine. Schizophr Res 202:391\u2013393","journal-title":"Schizophr Res"},{"issue":"1","key":"4169_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/JCP.0000000000002099","volume":"46","author":"MA-O Kuzin","year":"2025","unstructured":"Kuzin MA-O et al (2025) Fluvoxamine Augmentation of Clozapine and Dose-dependent Interaction Patterns: A Case Report. J Clin Psychopharmacol 46(1):113\u2013115","journal-title":"J Clin Psychopharmacol"},{"issue":"5","key":"4169_CR17","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1517\/17425255.2014.885504","volume":"10","author":"E Spina","year":"2014","unstructured":"Spina E, de Leon J (2014) Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opin Drug Metab Toxicol 10(5):721\u2013746","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"4169_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1742-7843.2007.00017.x","volume":"100","author":"E Spina","year":"2007","unstructured":"Spina E, de Leon J (2007) Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 100(1):4\u201322","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4","key":"4169_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/bcpt.13421","volume":"127","author":"M-O Kuzin","year":"2020","unstructured":"Kuzin M-O et al (2020) Pharmacokinetic interactions between clozapine and sertraline in smokers and non-smokers. Basic Clin Pharmacol Toxicol 127(4):303\u2013308","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"4169_CR20","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/bcpt.12655","volume":"120","author":"JT Horsfall","year":"2016","unstructured":"Horsfall JT, Sprague JE (2016) The pharmacology and toxicology of the \u201choly trinity.\u201d Basic Clin Pharmacol Toxicol 120(2):115\u2013119","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"5","key":"4169_CR21","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1152\/jn.00017.2021","volume":"125","author":"JM Ramirez","year":"2021","unstructured":"Ramirez JM et al (2021) Neuronal mechanisms underlying opioid-induced respiratory depression: our current understanding. J Neurohysiology 125(5):1899\u20131919","journal-title":"J Neurohysiology"},{"issue":"6","key":"4169_CR22","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/j.bja.2018.12.023","volume":"122","author":"MH Algera","year":"2019","unstructured":"Algera MH et al (2019) Opioid-induced respiratory depression in humans: a review of pharmacokinetic-pharmacodynamic modelling of reversal. Br J Anaersthesia 122(6):e168\u2013e179","journal-title":"Br J Anaersthesia"},{"issue":"7","key":"4169_CR23","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1046\/j.1360-0443.1999.9479612.x","volume":"94","author":"JM White","year":"1999","unstructured":"White JM, Irvine RJ (1999) Mechanisms of fatal opioid overdose. Addiction 94(7):961\u2013972","journal-title":"Addiction"},{"key":"4169_CR24","unstructured":"FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. (2017) 9\/20\/2017 [cited 2026; Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-about-serious-risks-and-death-when-combining-opioid-pain-or#:~:text=Safety%20Announcement,anxiety%2C%20insomnia%2C%20and%20seizures"},{"issue":"3","key":"4169_CR25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.18553\/jmcp.2016.22.3.263","volume":"22","author":"Y Liu","year":"2016","unstructured":"Liu Y, Qian C, Yang M (2016) Treatment Patterns Associated with ACR-Recommended Medications in the Management of Fibromyalgia in the United States. J Managed Care Specialty Pharm 22(3):263\u2013271","journal-title":"J Managed Care Specialty Pharm"},{"issue":"2","key":"4169_CR26","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1124\/jpet.109.151142","volume":"329","author":"LA Gonzalez","year":"2009","unstructured":"Gonzalez LA et al (2009) Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther 329(2):827\u2013837","journal-title":"J Pharmacol Exp Ther"},{"issue":"1\u20132","key":"4169_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0014-2999(02)02735-8","volume":"458","author":"M Honda","year":"2003","unstructured":"Honda M, Nishida H, Fau - T, Ono, Ono H (2003) Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors. Eur J Pharmacol 458(1\u20132):91\u201399","journal-title":"Eur J Pharmacol"},{"key":"4169_CR28","unstructured":"Drug Label FDA (2025) : Tizanidine Hydrochloride ; Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=7f39499a-98cf-4d13-9b07-ccb5c22e43c8#sec_ID_992e0977-8520-4027-a877-a06e2a322dd6"},{"issue":"1","key":"4169_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/cpt.1807","volume":"108","author":"Y Li","year":"2020","unstructured":"Li Y et al (2020) Risk of opioid overdose associated with concomitant use of opioids and skeletal muscle relaxants: a population-based cohort study. Clin Pharmacol Ther 108(1):81\u201389","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"4169_CR30","first-page":"39576","volume":"10","author":"AN Edinoff","year":"2022","unstructured":"Edinoff AN et al (2022) Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors. Health Psychol Res 10(4):39576","journal-title":"Health Psychol Res"},{"key":"4169_CR31","unstructured":"FDA Drug Label: Tranylcypromide sulfate. (2025) [cited 2026; Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=6a0b609b-0625-4c26-91a1-59ee3ece3ddf#Section_5.2"},{"issue":"4","key":"4169_CR32","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1213\/ANE.0000000000006858","volume":"139","author":"HK Rosenbaum","year":"2024","unstructured":"Rosenbaum HK, Van den Eynde V, Gillman PK (2024) Expert opinion on anesthetic considerations for patients receiving a classic monoamine oxidase inhibitor. Anesth Analg 139(4):863\u2013866","journal-title":"Anesth Analg"},{"issue":"8","key":"4169_CR33","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1007\/s00204-018-2244-6","volume":"92","author":"BA-O Baldo","year":"2018","unstructured":"Baldo BA-O (2018) Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. Arch Toxicol 92(8):2457\u20132473","journal-title":"Arch Toxicol"},{"issue":"3","key":"4169_CR34","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0022-3565(25)10630-7","volume":"273","author":"EE Codd","year":"1995","unstructured":"Codd EE et al (1995) Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther 273(3):1263\u20131270","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"4169_CR35","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/bja\/aei210","volume":"95","author":"PK Gillman","year":"2005","unstructured":"Gillman PK (2005) Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaersthesia 95(4):434\u2013441","journal-title":"Br J Anaersthesia"},{"issue":"1","key":"4169_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00210-014-1056-3","volume":"388","author":"M Barann","year":"2015","unstructured":"Barann M et al (2015) Effects of opioids on human serotonin transporters. Naunyn Schmiedebergs Arch Pharmacol 388(1):43\u201349","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"10","key":"4169_CR37","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2169\/internalmedicine.2437-23","volume":"63","author":"T Jinnouchi","year":"2024","unstructured":"Jinnouchi T et al (2024) Lithium-induced Nephrogenic Diabetes Insipidus with Efficacy of Desmopressin in Combination with Thiazide Diuretics and Non-steroidal Anti-inflammatory Drugs: A Case Report with a Review of the Literature. Intern Med 63(10):1399\u20131404","journal-title":"Intern Med"},{"issue":"8","key":"4169_CR38","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40262-016-0370-y","volume":"55","author":"PR Finley","year":"2016","unstructured":"Finley PR (2016) Drug Interactions with Lithium: An Update. Clin Pharmacokinet 55(8):925\u2013941","journal-title":"Clin Pharmacokinet"},{"issue":"13","key":"4169_CR39","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1056\/NEJM197403282901324","volume":"290","author":"WL Dyson","year":"1974","unstructured":"Hurtig Hi Fau -, Dyson WL, Dyson WL (1974) Letter: Lithium toxicity enhanced by diuresis. N Engl J Med 290(13):748\u2013749","journal-title":"N Engl J Med"},{"issue":"4","key":"4169_CR40","volume":"17","author":"ALA Perrine","year":"2025","unstructured":"Perrine ALA et al (2025) Paradoxical anti-diuretic effects of thiazide and thiazide-like diuretics in diabetes insipidus: a systematic review. Cureus 17(4):e82247","journal-title":"Cureus"},{"key":"4169_CR41","doi-asserted-by":"crossref","unstructured":"Ludlow KRF, J.M., G. Ludlow Jm Fau - Owen, and, Owen G (1980) Diuretics are dangerous with lithium. The BMJ, 281(6236): p. 371","DOI":"10.1136\/bmj.281.6236.371"},{"key":"4169_CR42","doi-asserted-by":"crossref","unstructured":"Forrest LSF, Forrest Jn JN Jr. Fau - Heninger, and, Heninger GR (1973) Lithium-induced diabetes insipidus: manic symptoms, brain and electrolyte correlates, and chlorothiazide treatment. American Journal of Psychiatry, 130(9): pp. 1014-8","DOI":"10.1176\/ajp.130.9.1014"},{"key":"4169_CR43","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1113\/jphysiol.1995.sp020598","volume":"483","author":"SJ Walter","year":"1995","unstructured":"Walter SJ, Sampson DG, Fau - B, Shirley, Shirley DG (1995) A micropuncture study of renal tubular lithium reabsorption in sodium-depleted rats. J Physiol 483:473\u2013479","journal-title":"J Physiol"},{"issue":"1","key":"4169_CR44","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1177\/0310057X7700500110","volume":"5","author":"TE Oh","year":"1977","unstructured":"Oh TE (1977) Frusemide and lithium toxicity. Anaesth Intensive Care Med 5(1):60\u201362","journal-title":"Anaesth Intensive Care Med"},{"key":"4169_CR45","unstructured":"FDA Drug Label: Lithium Carbonate. (2023) [cited 2026; Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=d3284649-ed4c-4096-987b-4ac16b8278f2"},{"issue":"3","key":"4169_CR46","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/bdi.13154","volume":"24","author":"GA-O Schoretsanitis","year":"2022","unstructured":"Schoretsanitis GA-O et al (2022) Prevalence of impaired kidney function in patients with long-term lithium treatment: A systematic review and meta-analysis. Bipolar disorder 24(3):264\u2013274","journal-title":"Bipolar disorder"},{"issue":"6","key":"4169_CR47","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1176\/ajp.138.6.818","volume":"138","author":"G Spring","year":"1981","unstructured":"Spring G, Fau - Frankel M, Frankel M (1981) New data on lithium and haloperidol incompatibility. Am J Psychiatry 138(6):818\u2013821","journal-title":"Am J Psychiatry"},{"issue":"9","key":"4169_CR48","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1001\/jama.1974.03240090023018","volume":"230","author":"NH Cohen","year":"1974","unstructured":"Cohen NH, Cohen NH (1974) Lithium carbonate, haloperidol, and irreversible brain damage. JAMA 230(9):1283\u20137","journal-title":"JAMA"},{"key":"4169_CR49","unstructured":"FDA Drug Label: Haloperidol. (2025) ; Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=9763c044-7430-48f7-bf3e-da1c7c683955"},{"issue":"10","key":"4169_CR50","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/j.1552-4604.1996.tb04763.x","volume":"36","author":"SA Goldman","year":"1996","unstructured":"Goldman SA (1996) Lithium and neuroleptics in combination: is there enhancement of neurotoxicity leading to permanent sequelae? J Clin Pharmacol 36(10):951\u2013962","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"4169_CR51","first-page":"107","volume":"38","author":"JM Strayhorn","year":"1977","unstructured":"Strayhorn JM, Nash JL (1977) Severe neurotoxicity despite therapeutic serum lithium levels. Dis Nerv Syst 38(2):107\u2013111","journal-title":"Dis Nerv Syst"},{"issue":"8","key":"4169_CR52","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1176\/ajp.136.8.1099a","volume":"136","author":"GK Spring","year":"1979","unstructured":"Spring GK (1979) EEG observations in confirming neurotoxicity. Am J Psychiatry 136(8):1099\u20131100","journal-title":"Am J Psychiatry"},{"issue":"7","key":"4169_CR53","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1176\/ajp.136.7.963","volume":"136","author":"HY Meltzer","year":"1979","unstructured":"West Ap Fau -, Meltzer HY, Meltzer HY (1979) Paradoxical lithium neurotoxicity: a report of five cases and a hypothesis about risk for neurotoxicity. Am J Psychiatry 136(7):963\u2013966","journal-title":"Am J Psychiatry"},{"issue":"1","key":"4169_CR54","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0025-7125(16)30278-4","volume":"77","author":"SN Caroff","year":"1993","unstructured":"Caroff SN (1993) Neuroleptic malignant syndrome. Med Clin North Am 77(1):185\u2013202","journal-title":"Med Clin North Am"},{"issue":"11","key":"4169_CR55","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/00005053-198811000-00006","volume":"176","author":"G Addonizio","year":"1988","unstructured":"Addonizio G et al (1988) Increased extrapyramidal symptoms with addition of lithium to neuroleptics. J Nerv Ment Dis 176(11):682\u2013685","journal-title":"J Nerv Ment Dis"},{"issue":"5409","key":"4169_CR56","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/243520a0","volume":"243","author":"E Friedman","year":"1973","unstructured":"Friedman E, Gershon S (1973) Effect of Lithium on Brain Dopamine. Nature 243(5409):520\u2013521","journal-title":"Nature"},{"key":"4169_CR57","doi-asserted-by":"crossref","unstructured":"Klawans Hl Fau -, Goetz CG, S. Goetz Cg Fau - Perlik, and, Perlik S (1980) Tardive dyskinesia: review and update. American Journal of Psychiatry, 137(8): pp. 900-8","DOI":"10.1176\/ajp.137.8.900"},{"key":"4169_CR58","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1192\/bjp.136.2.191","volume":"136","author":"P Tyrer","year":"1980","unstructured":"Tyrer P, Fau - Alexander MS et al (1980) An extrapyramidal syndrome after lithium therapy. Br J Psychiatry 136:191\u2013194","journal-title":"Br J Psychiatry"},{"issue":"4","key":"4169_CR59","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1017\/S1092852922000906","volume":"28","author":"V Van den Eynde","year":"2023","unstructured":"Van den Eynde V et al (2023) The prescriber\u2019s guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression. CNS Spectr 28(4):427\u2013440","journal-title":"CNS Spectr"},{"issue":"2","key":"4169_CR60","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/jgs.19256","volume":"73","author":"SA-O Vordenberg","year":"2025","unstructured":"Vordenberg SA-O et al (2025) Clinician contributions to central nervous system-active polypharmacy among older adults with dementia in the United States. J Am Geriatr Soc 73(2):422\u2013430","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"4169_CR61","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1176\/appi.ps.20230156","volume":"75","author":"PM Hughes","year":"2024","unstructured":"Hughes PM et al (2024) Psychotropic Medication Prescribing Across Medical Providers, 2016\u20132019. Psychiatric Serv 75(5):477\u2013480","journal-title":"Psychiatric Serv"},{"issue":"1","key":"4169_CR62","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/1475-6773.13072","volume":"54","author":"TA-O Rhee","year":"2019","unstructured":"Rhee TA-O, Rosenheck RA (2019) Initiation of new psychotropic prescriptions without a psychiatric diagnosis among US adults: Rates, correlates, and national trends from 2006 to 2015. Health Serv Res 54(1):139\u2013148","journal-title":"Health Serv Res"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04169-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04169-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04169-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:11:13Z","timestamp":1789459873000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04169-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":62,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4169"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04169-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"237"}}